Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 vaccination in children with cancer receiving or recently completing therapy
ACTRN12613000264785Phase 3Recruiting
- Sponsor
- Te-Yu Hung
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 cohorts), sponsored by Te-Yu Hung. Primary endpoints: Protective serotype-specific IgG response and Protective opsonophagocytic assay response. Started Mar 2013; status: recruiting.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on ACTRN12613000264785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000264785.